Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 10/20 | 0.50 |
| ▸ | CNR1 | P21554 | 8/20 | 0.50 |
| ▸ | ACHE | P22303 | 6/20 | 0.50 |
| ▸ | MAPT | P10636 | 5/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | GLS | O94925 | 1/20 | 0.43 |
| ▸ | F2R | P25116 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | F2RL3 | Q96RI0 | 1/20 | 0.41 |
| ▸ | BCHE | P06276 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14923643 | 0.89 | CNR2 (0.42) | CNR2CNR1ACHEMAPTPOLB | |
| SCHEMBL14923625 | 0.86 | MAPT (0.51) | CNR2CNR1ACHEMAPTPOLB | |
| SCHEMBL14923447 | 0.84 | CNR2 (0.52) | CNR2CNR1ACHEMAPTPOLB | |
| SCHEMBL14908669 | 0.84 | CNR2 (0.44) | CNR2CNR1ACHEMAPTPOLB | |
| SCHEMBL14923487 | 0.82 | CNR2 (0.53) | CNR2CNR1ACHEMAPTPOLB | |
| SCHEMBL14908618 | 0.81 | L3MBTL1 (0.62) | CNR2CNR1ACHEMAPTPOLB | |
| SCHEMBL3376821 | 0.80 | CNR2 (0.54) | CNR2CNR1ACHEMAPTPOLB | |
| SCHEMBL3380035 | 0.76 | KMO (0.44) | CNR2CNR1ACHEMAPTPOLB | |
| SCHEMBL14909721 | 0.74 | CYP1A2 (0.48) | CNR2CNR1ACHEMAPTL3MBTL1 | |
| SCHEMBL14928249 | 0.74 | GLS (0.75) | CNR2CNR1ACHEMAPTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8895585-B2 | Nicotinamide derivative or salt thereof | FUJIFILM CORPORATION (JP) | 2014-11-25 | — | — | US | disclosed |
| US-8895585-B2 | Nicotinamide derivative or salt thereof | FUJIFILM CORPORATION (JP) | 2014-11-25 | — | — | US | disclosed |
| US-8809371-B2 | — | — | 2014-08-19 | — | — | US | disclosed |
| US-8809371-B2 | — | — | 2014-08-19 | — | — | US | disclosed |
| US-20130116430-A1 | NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF | FUJIFILM CORPORATION (JP) | 2013-05-09 | — | — | US | disclosed |
| US-20130116430-A1 | NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF | FUJIFILM CORPORATION (JP) | 2013-05-09 | — | — | US | disclosed |
| EP-2589592-A1 | NOVEL NICOTINAMIDE DERIVATIVES OR SALTS THEREOF | FUJIFILM Corporation (JP) | 2013-05-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116430-A1 | NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF | SYK, CD38, BTK | CNR2 305/4885CNR1 273/4885ACHE 4592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.